Pharmacology of Vitamin K (Phytomenadione)

Introduction/Overview

Vitamin K represents a group of fat-soluble vitamins essential for the post-translational modification of specific proteins, most notably those involved in the coagulation cascade. The term encompasses several structurally related naphthoquinone compounds, with phytomenadione (Vitamin K₁, phylloquinone) being the primary natural form obtained from dietary sources such as green leafy vegetables. As a therapeutic agent, phytomenadione is a critical medication in the management and prevention of hemorrhagic disorders resulting from vitamin K deficiency or antagonism. Its clinical importance is underscored by its role as the specific antidote for over-anticoagulation with vitamin K antagonists like warfarin, and in the prevention of hemorrhagic disease of the newborn. Understanding the pharmacology of phytomenadione is fundamental for the safe and effective management of coagulation disorders across various patient populations.

Learning Objectives

• Describe the biochemical mechanism of action of phytomenadione in the synthesis of functional vitamin K-dependent clotting factors.
• Compare and contrast the pharmacokinetic profiles of oral, subcutaneous, and intravenous phytomenadione administration, including associated risks.
• Identify the primary therapeutic indications for phytomenadione, including the reversal of vitamin K antagonist anticoagulation and the management of deficiency states.
• Analyze the major adverse effects and serious risks, such as anaphylactoid reactions, associated with different routes of phytomenadione administration.
• Evaluate special considerations for phytomenadione use in populations including neonates, pregnant women, and patients with hepatic impairment.

Classification

Phytomenadione is classified primarily as a vitamin, specifically Vitamin K₁. From a therapeutic perspective, it is categorized as a hemostatic agent and, more specifically, a procoagulant vitamin or antidote for vitamin K antagonist poisoning. It is distinct from the menaquinones (Vitamin K₂ series), which are synthesized by bacterial flora and have differing pharmacokinetic and potentially pharmacodynamic profiles.

Chemical Classification

Phytomenadione is a 2-methyl-3-phytyl-1,4-naphthoquinone. Its chemical structure consists of a methylated naphthoquinone ring and a phytyl side chain. This side chain, a saturated 20-carbon terpenoid, differentiates it from the menaquinones, which possess an unsaturated polyisoprenoid side chain of varying length. The synthetic, water-soluble derivatives (e.g., menadione sodium bisulfite) are no longer commonly used therapeutically due to associated toxicity risks, particularly hemolytic anemia and kernicterus in neonates. Consequently, phytomenadione remains the formulation of choice for clinical use.

Mechanism of Action

The pharmacodynamic action of phytomenadione is fundamentally enzymatic and post-translational, serving as an essential cofactor for the enzyme γ-glutamyl carboxylase. This action is required for the synthesis of biologically active forms of several clotting factors and other proteins.

Molecular and Cellular Mechanisms

Vitamin K-dependent clotting factors (Factors II, VII, IX, and X) and anticoagulant proteins (Proteins C and S) are synthesized in the liver as inactive precursor proteins. These precursors contain specific glutamic acid (Glu) residues within their N-terminal regions. The enzyme γ-glutamyl carboxylase catalyzes the conversion of these Glu residues to γ-carboxyglutamic acid (Gla) residues. This carboxylation reaction is coupled to the oxidation of the reduced, active form of vitamin K (vitamin K hydroquinone) to vitamin K 2,3-epoxide. The newly formed Gla residues confer upon these proteins the ability to bind calcium ions. This calcium binding induces a conformational change that allows the proteins to interact with phospholipid surfaces, such as those provided by activated platelets at sites of vascular injury, which is an absolute requirement for their procoagulant or anticoagulant activity.

For the cycle to continue, the vitamin K 2,3-epoxide must be recycled back to the active hydroquinone form. This regeneration is accomplished by a two-step reduction process. First, vitamin K epoxide reductase (VKOR) reduces the epoxide to vitamin K quinone. Subsequently, vitamin K quinone reductase reduces the quinone back to the active hydroquinone. This recycling pathway is critically important for the maintenance of vitamin K stores and is the primary target of the coumarin anticoagulants (e.g., warfarin), which inhibit VKOR. Phytomenadione administration provides substrate to overcome this blockade, allowing the carboxylation cycle to proceed and enabling the synthesis of functional clotting factors.

The therapeutic effect is not immediate, as it depends on the de novo synthesis of these factors. The onset of action correlates with the synthesis rate of the individual factors, with Factor VII (half-life ≈ 6 hours) appearing first, followed by Factor IX (≈24 hours), Factor X (≈40 hours), and Factor II (prothrombin, ≈60 hours). Full reversal of anticoagulation typically requires 24 to 48 hours.

Pharmacokinetics

The pharmacokinetic profile of phytomenadione is significantly influenced by its lipophilic nature and the route of administration, which in turn dictates its therapeutic application and risk profile.

Absorption

Oral absorption of phytomenadione from the gastrointestinal tract is bile-dependent, requiring the presence of bile salts for emulsification and formation of mixed micelles to facilitate uptake via enterocytes. Absorption is therefore impaired in conditions associated with cholestasis, biliary obstruction, or severe malabsorption syndromes. Under normal physiological conditions with adequate bile flow, oral bioavailability is variable but may be estimated at approximately 50-80% when taken with a meal containing fat, which enhances absorption. Absorption following intramuscular (IM) or subcutaneous (SC) administration is generally reliable but can be slow and unpredictable in critically ill or hypoperfused patients.

Distribution

Following absorption, phytomenadione is incorporated into chylomicrons and enters the circulation via the lymphatic system. It is initially taken up by the liver, which is the primary site of action, where it is incorporated into very-low-density lipoproteins (VLDLs) before being redistributed to other tissues. The volume of distribution is relatively limited, reflecting its extensive binding to plasma lipoproteins and tissue membranes. It does not cross the placenta readily, and only minimal amounts are excreted into breast milk.

Metabolism

Hepatic metabolism of phytomenadione is extensive and involves the cyclic oxidation and reduction described in its mechanism of action. The primary inactive metabolites are the epoxide and hydroxylated forms, which are conjugated to glucuronide and sulfate derivatives. These conjugated metabolites are excreted in bile and undergo enterohepatic recirculation, with ultimate excretion in feces. A small fraction of metabolites may be excreted renally.

Excretion

Elimination occurs predominantly via the biliary-fecal route, with approximately 70-80% of a dose excreted as metabolites in feces over several days. Renal excretion accounts for less than 10% of total elimination. The terminal elimination half-life is difficult to define precisely due to tissue storage and recycling but is generally considered to be 1 to 2 hours for the parent compound, while the biological effect, governed by the synthesis and degradation of clotting factors, persists for much longer.

Dosing Considerations

The route of administration is a critical determinant of both efficacy and safety. Oral administration is preferred for the routine correction of excessive INR elevation in stable patients on warfarin. Subcutaneous administration, while once common, is now less favored due to erratic and delayed absorption. Intravenous administration provides the most rapid and predictable increase in vitamin K-dependent factor synthesis but carries the highest risk of severe anaphylactoid reactions. When IV administration is necessary, it should be administered by slow infusion, typically over 20-30 minutes, at a rate not exceeding 1 mg per minute, with careful patient monitoring. Dosing is highly indication-specific, ranging from 0.5-1 mg for newborn prophylaxis to 5-10 mg for warfarin reversal.

Therapeutic Uses/Clinical Applications

The clinical use of phytomenadione is targeted at conditions characterized by a functional deficiency of vitamin K-dependent coagulation factors.

Approved Indications

Reversal of Vitamin K Antagonist (VKA) Anticoagulation: This is the most common therapeutic application. Phytomenadione is indicated for the urgent or non-urgent correction of excessively prolonged prothrombin time (PT/INR) due to drugs like warfarin, acenocoumarol, or phenprocoumon. The dose and route depend on the clinical scenario: for asymptomatic patients with an INR above the therapeutic range but below 10, low-dose oral phytomenadione (1-2.5 mg) is often sufficient. For life-threatening bleeding or major over-anticoagulation (e.g., INR >20), intravenous phytomenadione (5-10 mg) is administered concomitantly with 4-factor prothrombin complex concentrate (PCC) or fresh frozen plasma (FFP) for immediate hemostatic correction.

Prophylaxis and Treatment of Hemorrhagic Disease of the Newborn (HDN): All newborns receive a single intramuscular dose (0.5-1 mg) shortly after birth to prevent classic HDN, which results from low placental transfer of vitamin K, a sterile gut at birth, and low vitamin K content in breast milk. Phytomenadione is also the treatment for active HDN.

Vitamin K Deficiency in Adults: Deficiency can arise from malnutrition, malabsorption syndromes (e.g., cystic fibrosis, celiac disease, short bowel syndrome), chronic liver disease (impaired storage and use), prolonged use of broad-spectrum antibiotics (which reduce gut flora synthesis of menaquinones), and obstructive jaundice. Correction involves treating the underlying cause and administering replacement phytomenadione.

Management of Poisoning with Superwarfarin Rodenticides: Long-acting anticoagulant rodenticides (e.g., brodifacoum) are potent, long-acting VKOR inhibitors. Poisoning requires prolonged, high-dose oral phytomenadione therapy, sometimes for weeks to months, guided by frequent INR monitoring.

Off-Label Uses

Reversal of Direct Oral Anticoagulants (DOACs): Phytomenadione is not effective for reversing the effects of factor Xa inhibitors (e.g., apixaban, rivaroxaban) or direct thrombin inhibitors (e.g., dabigatran). Its use is reserved for cases where concomitant VKA use or underlying vitamin K deficiency is suspected.

Support in Liver Disease: In patients with advanced cirrhosis, synthesis of clotting factors is impaired due to hepatocellular dysfunction, not solely due to vitamin K deficiency. A trial of phytomenadione may be given, but a lack of INR response indicates that the coagulopathy is synthetic rather than nutritional.

Adverse Effects

Adverse effects associated with phytomenadione are generally uncommon but can be severe, with risk strongly correlated to the route and speed of administration.

Common Side Effects

These are typically mild and transient. With oral administration, gastrointestinal disturbances are rare. Following intramuscular or subcutaneous injection, local reactions such as pain, swelling, or hematoma at the injection site may occur, particularly in anticoagulated patients. Transient flushing, dizziness, or alterations in taste have been reported with intravenous use.

Serious and Rare Adverse Reactions

The most significant risk is anaphylaxis and anaphylactoid reactions, which are almost exclusively associated with intravenous administration. These reactions, characterized by hypotension, dyspnea, chest tightness, urticaria, and cardiovascular collapse, may be related to the rate of infusion or the emulsifying agent (e.g., polyoxyethylated fatty acid derivative) used in some formulations. Consequently, IV phytomenadione should be reserved for situations where the benefit outweighs this risk and should be infused slowly with resuscitation equipment available.

Hyperbilirubinemia and Kernicterus: This was a major concern with the use of water-soluble synthetic vitamin K analogues (menadione) in neonates, particularly premature infants. Phytomenadione, in the recommended prophylactic dose (0.5-1 mg IM), has not been associated with an increased risk of kernicterus.

Thrombotic Events: Rapid reversal of anticoagulation in patients with a pre-existing hypercoagulable state (e.g., patients with mechanical heart valves or recent deep vein thrombosis) could theoretically precipitate thrombosis. This risk is mitigated by using the lowest effective dose and combining phytomenadione with therapeutic heparin bridging when appropriate.

Black Box Warnings

Intravenous formulations of phytomenadione may carry a black box warning in some jurisdictions regarding the potential for severe, potentially fatal, hypersensitivity and anaphylactoid reactions, even when diluted and administered cautiously. The warning typically emphasizes that the intravenous route should be restricted to situations where other routes are not feasible and the clinical situation warrants the risk.

Drug Interactions

The most critical interactions involve drugs that affect vitamin K status, absorption, or the coagulation cascade.

Major Drug-Drug Interactions

Vitamin K Antagonists (Warfarin, etc.): This is a therapeutic interaction. Phytomenadione directly antagonizes the anticoagulant effect. Excessive or inappropriate dosing can lead to resistance to subsequent warfarin therapy for several days to weeks, making re-anticoagulation challenging.

Orlistat and Bile Acid Sequestrants: Orlistat (a lipase inhibitor) and cholestyramine or colestipol can impair the absorption of fat-soluble vitamins, including phytomenadione, potentially reducing its efficacy when administered orally.

Broad-Spectrum Antibiotics: Long-term use can reduce the intestinal synthesis of vitamin K₂ by gut flora, potentially increasing the requirement for exogenous vitamin K or enhancing the effect of warfarin. This may necessitate adjustment of VKA dose or phytomenadione supplementation.

Cytochrome P450 Inducers: Drugs such as rifampin, carbamazepine, and phenobarbital may increase the metabolism of both warfarin and vitamin K, creating a complex interaction that requires careful INR monitoring.

Contraindications

There are few absolute contraindications. Known hypersensitivity to phytomenadione or any component of the formulation (particularly the solubilizing agents in parenteral preparations) contraindicates its use. Relative contraindications include situations where rapid reversal of anticoagulation could pose a significant thrombotic risk, such as in patients with recent arterial thrombosis or with mechanical heart valves who are not adequately bridged with heparin. In these cases, the risks and benefits must be carefully weighed, and reversal is often managed with specific factor concentrates (PCC) with minimal or no phytomenadione.

Special Considerations

Use in Pregnancy and Lactation

Phytomenadione is classified as FDA Pregnancy Category C. Animal reproduction studies have not been conducted, and adequate, well-controlled studies in pregnant women are lacking. It is used when clearly needed, such as for reversal of warfarin anticoagulation in a pregnant woman experiencing bleeding. It crosses the placenta poorly. Warfarin embryopathy is related to direct drug exposure, not vitamin K deficiency, so phytomenadione administration to the mother does not prevent it. For neonates, prophylaxis is standard. During lactation, phytomenadione is excreted in breast milk in low amounts, but oral supplementation to the mother is not considered necessary for the infant’s adequacy, as the infant receives postnatal prophylaxis.

Pediatric Considerations

The primary pediatric use is prophylaxis against HDN. The recommended dose is 0.5 to 1 mg intramuscularly within 6 hours of birth. For premature infants, a dose of 0.5 mg is often used. Oral regimens (multiple doses over weeks) exist but are associated with a higher failure rate for preventing late HDN and are not recommended as first-line in many guidelines. For the reversal of VKA in children, dosing is weight-based, typically 0.03-0.1 mg/kg IV, not to exceed adult doses.

Geriatric Considerations

Elderly patients may have an increased sensitivity to warfarin due to age-related changes in pharmacokinetics, comorbid conditions, and polypharmacy. They may therefore require lower doses of phytomenadione for INR correction. Age-related decline in hepatic or renal function does not significantly alter phytomenadione pharmacokinetics, but comorbid malabsorption or poor nutritional status may necessitate therapy.

Renal and Hepatic Impairment

Renal Impairment: Dose adjustment is not typically required, as renal excretion is minimal. However, patients with advanced renal disease often have complex coagulopathies and may be on multiple medications, requiring careful monitoring.

Hepatic Impairment: This is a critical consideration. Severe liver disease impairs the synthesis of all clotting factors, not just the vitamin K-dependent ones. While a trial of phytomenadione may be warranted to correct any superimposed nutritional deficiency, a poor or absent response in the INR indicates that the coagulopathy is due to synthetic liver failure. In such cases, phytomenadione is ineffective, and management relies on factor replacement (e.g., PCC, FFP) if bleeding occurs.

Summary/Key Points

• Phytomenadione (Vitamin K₁) is an essential cofactor for γ-glutamyl carboxylase, the enzyme required for the synthesis of functional vitamin K-dependent clotting factors (II, VII, IX, X) and anticoagulant proteins (C and S).
• Its mechanism involves a cyclic oxidation-reduction process that is directly inhibited by vitamin K antagonist anticoagulants like warfarin.
• Pharmacokinetics are route-dependent: oral absorption is bile- and fat-dependent, subcutaneous absorption can be erratic, and intravenous administration provides the most predictable effect but carries the highest risk of severe anaphylactoid reactions.
• Primary therapeutic indications include reversal of VKA over-anticoagulation, prophylaxis and treatment of hemorrhagic disease of the newborn, and correction of vitamin K deficiency from various causes.
• The most serious adverse effect is anaphylaxis, which is strongly associated with rapid intravenous infusion. Formulations contain solubilizing agents that may contribute to this risk.
• Key drug interactions involve warfarin (therapeutic antagonism) and drugs that impair fat-soluble vitamin absorption (e.g., orlistat, bile acid sequestrants).
• In hepatic impairment, a lack of INR response to phytomenadione indicates that coagulopathy is due to synthetic failure rather than vitamin deficiency.

Clinical Pearls

• For warfarin reversal, the route dictates speed and risk: Oral for non-urgent correction in stable patients, IV (slow infusion) for serious bleeding combined with factor replacement, and generally avoid SC due to unpredictable absorption.
• The onset of action is not immediate; it depends on hepatic synthesis of new factors. Factor VII levels rise first (≈6 hr), but full reversal takes 24-48 hours. For immediate hemostasis in bleeding, co-administer 4-factor PCC or FFP.
• In neonates, intramuscular phytomenadione (0.5-1 mg) is the standard of care for preventing HDN. Oral multidose regimens have a higher failure rate for preventing late-onset disease.
• When faced with a coagulopathic patient with liver disease, a trial of phytomenadione can be diagnostic: improvement in INR suggests a component of correctable deficiency, while no change points to severe synthetic dysfunction.
• Always consider the thrombotic risk of rapid anticoagulation reversal, particularly in patients with mechanical heart valves or recent thrombosis. A multidisciplinary approach involving hematology and cardiology is often prudent.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
4. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.